In Preclinical Model of Ovarian Cancer, the SGK1 Inhibitor SI113 Counteracts the Development of Paclitaxel Resistance and Restores Drug Sensitivity

Ovarian cancer is the second most common gynecological malignancy worldwide. Paclitaxel is particularly important in the therapy of ovarian carcinomas, but the treatment efficacy is counteracted by the development of resistance to chemotherapy. The identification of target molecules that can prevent...

Descripción completa

Detalles Bibliográficos
Autores principales: D'Antona, Lucia, Dattilo, Vincenzo, Catalogna, Giada, Scumaci, Domenica, Fiumara, Claudia Vincenza, Musumeci, Francesca, Perrotti, Giuseppe, Schenone, Silvia, Tallerico, Rossana, Spoleti, Cristina B., Costa, Nicola, Iuliano, Rodolfo, Cuda, Giovanni, Amato, Rosario, Perrotti, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545392/
https://www.ncbi.nlm.nih.gov/pubmed/31163384
http://dx.doi.org/10.1016/j.tranon.2019.05.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545392/
https://www.ncbi.nlm.nih.gov/pubmed/31163384
http://dx.doi.org/10.1016/j.tranon.2019.05.008

Ejemplares similares